Testing Ticagrelor + aspirin for NSTEMI - non-ST segment elevation MI
Official title: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)
- Phase 3
- 2 groups
- One site, in Montreal
- Recruiting
Interventions
- Medication
Ticagrelor + placebo
Ticagrelor 90 mg twice daily + placebo once daily
- Medication
Ticagrelor + aspirin
Ticagrelor 90 mg twice daily + aspirin 80 mg once daily
Canadian Sites (1)
1 of 1 recruiting
- Recruiting
Montreal Heart Institute
Montreal, Quebec
Eligibility Criteria
See who this study is looking for16 criteria
The trial’s own eligibility text, word for word from the registry. Only the trial site can say who takes part.
Inclusion
- +Age ≥18 years;
- +Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
- +Coronary angiogram performed;
- +Planned for medical management alone, without revascularization;
- +Willingness to participate and to attend study visits;
- +Expected life expectancy ≥12 months.
Exclusion
- −Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
- −Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
- −Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
- −Elevations in cardiac biomarkersBiomarkerSomething measurable in the body used as a signal of what is happening.Read more → (troponins or CK-MB) that is believed by the investigatorPrincipal investigatorThe doctor or researcher responsible for running the study at a site.Read more → not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
- −Confirmed or suspected spontaneous coronary artery dissection;
- −Concomitant indication for chronic oral anticoagulant;
- −Concomitant non-coronary indication for dual antiplatelet therapy;
- −Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
- −Previous hospitalization for MI, PCI, or CABG within 12 months;
- −Unsuitability for either randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → treatment, based on the judgement of the treating physician
In plain language
Assembled directly from this trial’s registry record. Every sentence traces to a field below — nothing here is generated or interpreted.
What this study is
This study is testing a treatment for a condition.
Phase 3Phase 3A large study comparing a treatment against the current standard.Read more → — a large study comparing this against the current standard, usually across many hospitals.
From the trial registry
Built from these fields:
- designModule.designInfo.primaryPurpose
- designModule.phases
Who receives what
There are 2 groups in this study.
Group A receives Ticagrelor + placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more →.
Registry label: A: Ticagrelor monotherapy
Group B, the comparison group, receives Ticagrelor + aspirin.
Registry label: B: DAPT with ticagrelor and aspirin
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].label
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
How the study is run
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
You, the study team, the people giving the treatment, and the people analysing the results would all be kept unaware of which group you are in until the study ends.
From the trial registry
Built from these fields:
- designModule.designInfo.allocation
- designModule.designInfo.maskingInfo.masking
Is there a placebo?
One group receives a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → — a dummy treatment with no active medicine in it — alongside the other treatment that group is given.
One group receives an existing treatment, so the two can be compared.
From the trial registry
Built from these fields:
- armsInterventionsModule.armGroups[].type
- armsInterventionsModule.armGroups[].interventionNames
Who the study is looking for
The study lists a minimum age of 18 years, with no upper limit given.
The study is open to people of any sex.
The study does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
These are the criteria the study lists. Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part.
From the trial registry
Built from these fields:
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How big and how long
The study aims to enrol about 2,570 people.
The study is currently expected to finish around January 2031.
The main measurement is taken over: From randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → to 12 months.
From the trial registry
Built from these fields:
- designModule.enrollmentInfo.count
- statusModule.completionDateStruct.date
- outcomesModule.primaryOutcomes[].timeFrame
What the study measures
Bleeding — measured over From randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → to 12 months.
Patient-oriented ischemic clinical endpointEndpointThe specific thing a study measures to answer its question.Read more → — measured over From randomization to 12 months.
From the trial registry
Built from these fields:
- outcomesModule.primaryOutcomes[].measure
- outcomesModule.primaryOutcomes[].timeFrame
Source: NCT07257198 on ClinicalTrials.gov. The full registry text is further down this page — this summary never replaces it.
Not medical advice. What do these terms mean?
What is being tested — in plain terms
About Ticagrelor + placeboDrug
Ticagrelor 90 mg twice daily + placebo once daily
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
About Ticagrelor + aspirinDrug
Ticagrelor 90 mg twice daily + aspirin 80 mg once daily
From the trial registry — its own words, unedited.
What a drug is here: A medicine — a chemical or small-molecule treatment — given as the thing being studied.
Read the full explanation → · in clinical review
Common questions
Answered from this trial’s registry record. Where the record doesn’t say, these answers say so rather than filling the gap.
Am I eligible for this trial?
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can decide whether someone can take part. Concord cannot make that determination, and neither can any tool that has not examined you.
What the study lists: a minimum age of 18 years.
The full inclusionInclusion criteriaThe things you must have or be for a study to consider you.Read more → and exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → are published on this page, exactly as the study team wrote them.
The useful next step is to bring this trial to your doctor. Answering a few questions first gives them something concrete to review.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.eligibilityCriteria
Is there a placebo?
Yes. One group receives a placeboPlaceboA dummy treatment with no active medicine, used for comparison.Read more → — a dummy treatment with no active medicine in it — alongside the other treatment that group is given.
One group receives an existing treatment so the two can be compared.
From the trial registry
- armsInterventionsModule.armGroups[].type
Would I know which treatment I am getting?
You, the study team, the people giving the treatment, and the people analysing the results would all be kept unaware of which group you are in until the study ends.
Which group you would be placed in is decided by chance, like a coin flip — not by you and not by your doctor.
From the trial registry
- designModule.designInfo.maskingInfo.masking
- designModule.designInfo.allocation
Who can join?
The study lists a minimum age of 18 years, with no upper limit given.
It is open to people of any sex.
It does not accept healthy volunteersHealthy volunteerSomeone without the condition being studied who takes part anyway.Read more →.
Only the trial siteTrial siteA hospital or clinic where a study is actually run.Read more → can confirm whether a particular person can take part.
From the trial registry
- eligibilityModule.minimumAge
- eligibilityModule.sex
- eligibilityModule.healthyVolunteers
How long would this take?
The study's main measurement is taken over: From randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → to 12 months.
The study as a whole is currently expected to finish around 2031-01-01.
How long any one person takes part can differ from the study length. The study team can tell you what the schedule looks like in practice.
From the trial registry
- outcomesModule.primaryOutcomes[].timeFrame
- statusModule.completionDateStruct.date
How many people are taking part?
The study aims to enrol about 2,570 people.
From the trial registry
- designModule.enrollmentInfo.count
Where is this happening?
This study lists one location: Montreal, Quebec, Canada.
Sites can open and close during a study, so confirm with the team before travelling.
From the trial registry
- trial_locations
About This Trial
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
Think this trial might be right for you?
Complete a quick intake form and we will match you with this and other relevant trials based on your medical profile.
See if this trial could fit youThis page is for informational purposes only and does not constitute medical advice. Clinical trial eligibility can only be determined by the trial site after proper screening. Trial information is sourced from ClinicalTrials.gov and may not reflect the most current status. Always consult your healthcare provider before making decisions about clinical trial participation.